Latest Share Chat

REMOVE ADS

Glaxosmithkline Share News (GSK)

Glaxosmithkline Information

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes

Get Live Data

1,903.50 0.00 (0.00%)

Bid:

1,840.00

Ask:

1,999.00

Spread: 159.00 (8.641%)

Market Cap: £76.31b

Last checked at -

Intraday Glaxosmithkline Share Chart

REMOVE ADS

Glaxosmithkline News

GSK ends cUTI trial early as Spero joint product meets efficacy goal

(Alliance News) - GSK PLC on Wednesday said it will stop a late-stage trial early for an investigational oral antibiotic to treat complicated urinary ...

LONDON MARKET CLOSE: Stocks down before long weekend, Powell's speech

(Alliance News) - Stock prices in London closed in the red on Friday, following US President Donald Trump's renewed tariff threats against the EU and ...

GSK hails positive EU opinion of blood cancer treatment Blenrep

(Alliance News) - GSK PLC on Friday said its drug Blenrep has received a "positive opinion" from the European Medicines Agency's Committee for Medicin...

LONDON MARKET OPEN: European stocks rise as bond yields ease

(Alliance News) - European stocks opened higher on Friday, as a cooling of US yields calmed some investor nerves, while improved UK data boosted sterl...

GSK's Nucala wins FDA approval for COPD with eosinophilic inflammation

(Alliance News) - GSK PLC on Thursday said the US Food & Drug Administration has approved its asthma drug Nucala as an add-on maintenance treatment fo...

GSK's COPD treatment approved by FDA

(Sharecast News) - Pharma group GSK has announced that US regulators have approved for use its Nucala treatment for adults with chronic obstructive pu...

GSK wins approval in Japan for Blenrep combination as myeloma therapy

(Alliance News) - GSK PLC on Monday said it has received approval in Japan for Blenrep combinations in the treatment of adults with relapsed or refrac...

GSK's blood cancer treatment approved in Japan

(Sharecast News) - GSK's Blenrep treatment has been approved by Japanese regulators when in combination for relapsed or refractory multiple myeloma, m...